LOS ANGELES--(BUSINESS WIRE)--Response Genetics, Inc. (Nasdaq: RGDX), a company focused on the development and sale of molecular diagnostic tests for cancer, today announced consolidated financial results for the 12 months ending December 31, 2008, and the fourth quarter of 2008, as well as an update on the Company’s ResponseDX™ sales activities.
